Skip to main content
SpringerLink
Log in

Novartis Oncology comments on MCA's decision to endorse use of anastrozole in estrogen-receptor positive early breast cancer

  • Media release
  • Published:
Inpharma Weekly

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novartis Oncology comments on MCA's decision to endorse use of anastrozole in estrogen-receptor positive early breast cancer. Inpharma Wkly. 1364, 3 (2002). https://doi.org/10.2165/00128413-200213640-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-200213640-00003

Keywords

Search

Navigation